Summary
Johnson & Johnson is a Dividend King that recently raised their dividend for the 56th consecutive year.
Packed with a well diversified portfolio, JNJ can thrive in any economic backdrop.
The stock's recent run has lessened the discount seen during the first half of the year as it looks closer to fair value rather than trading at a discount.
The relaunch of the company's famed Johnson's Baby products resonated with consumers in Q3 to the liking of 4.3% growth within the baby care segment.
Johnson & Johnson (JNJ) re-launched their Johnson Baby products line in Q3 to rave reviews from consumers. The company revamped their products to become more natural by lessening the number of chemicals with the hopes of gaining the attention of the millennial parents. Pharmaceuticals continue to perform well and excite us going forward as the company has a loaded pipeline, which bodes well as the segment makes up 50% of company revenues. With the market looking unstable, and a bull market looking long in the tooth, now may soon be the time to start building a position in a defensive name like JNJ
Source: JNJ Investor Relations
